This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

The EURO-SHOCK Trial version 1

  • Research type

    Research Study

  • Full title

    EURO SHOCK Testing the value of novel strategy and its cost efficacy in order to improve the poor outcomes in Cardiogenic Shock

  • IRAS ID

    250403

  • Contact name

    Anthony Gershlick

  • Contact email

    ahg8@le.ac.uk

  • Sponsor organisation

    University of Leicester

  • Clinicaltrials.gov Identifier

    NCT03813134

  • Duration of Study in the UK

    4 years, 9 months, 29 days

  • Research summary

    This study involves patients who suffer from Cardiogenic shock (CGS). This happens in 10% of people who have had a heart attack. In this small group of patients 45-50% die within 30 days. To date there have been no research studies that have had any impact on this statistic in the last 20 years.
    The Euro Shock Trial is supported by the European Union Horizons 2020 programme, and is testing the benefits or otherwise a device called ECMO (Extra Corporeal Membrane Oxygenation) therapy which has been shown to support the heart while it recovers from heart attacks.
    We will be randomising 428 patients with CGS from 44 EU centres to either standard treatment [stent and drug therapy] or standard treatment PLUS early intervention with ECMO therapy. ECMO therapy is expensive and usually takes place in specialised centres, so we want to see if this therapy is effective and value for money.
    There will also be sub studies that will also add to the body of knowledge in this area and we will undertake blood sampling, non-invasive scans and data analyses during the patients’ treatment.They will help us understand why ECMO has worked (or not).

  • REC name

    Yorkshire & The Humber - Leeds West Research Ethics Committee

  • REC reference

    19/YH/0003

  • Date of REC Opinion

    4 Mar 2019

  • REC opinion

    Further Information Favourable Opinion